Monomeric Fc-Fusion Proteins

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Volumn , Issue , 2013, Pages 107-121

  Mei, Baisong ^a   Low, Susan C ^a   Krassova, Snejana ^a   Peters, Robert T ^a   Pierce, Glenn F ^a   Dumont, Jennifer A ^a  

^a BIOGEN   (United States)

Author keywords

Alternative applications; Cytokine Fc FPs; FcRn expression; Monomeric Fc FPs; Monomeric, purification

Indexed keywords

EID: 84886119311     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354599.ch7     Document Type: Chapter

References (100)

1. Morell A, Terry WD, Waldmann TA. (1970) Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49, 673-680.
2. Waldmann TA, Strober W. (1969) Metabolism of immunoglobulins. Prog. Allergy 13, 1-110.
3. Simister NE, Mostov KE. (1989) An Fc receptor structurally related to MHC class I antigens. Nature 337, 184-187.
4. Brambell F. (1966) The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 2, 1087-1093.
5. Rodewald R, Kraehenbuhl JP. (1984) Receptor-mediated transport of IgG. J. Cell Biol. 99, 159s-164s.
6. Ghetie V, Hubbard JG, Kim J-K, TsenM-F, Lee Y,Ward ES. (1996) Abnormally short serum half-lives of IgG in b2-microglobulin-deficient mice. Eur. J. Immunol. 26, 690-696.
7. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. (1996) Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 89, 573-578.
8. Junghans RP, Anderson CL. (1996) The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. PNAS USA 93, 5512-5516.
9. Waldmann TA, Terry WD. (1990) Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J. Clin. Invest. 86, 2093-2098.
10. Wani MA, Haynes LD, Kim J, Bronson CL, Chaudhury C, Mohanty S, et al. (2006) Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant I22-microglobulin gene. PNAS USA 103, 5084-5089.
11. Akilesh S, Huber TB,Wu H,Wang G, Hartleben B, Kopp JB, et al. (2008) Podocytes use FcRn to clear IgG from the glomerular basement membrane. PNAS USA 105, 967-972.
12. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, et al. (2004) Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. PNAS USA 101, 9763-9768.
13. Blumberg RS, Koss T, Story CM, Barisani D, Polischuk J, Lipin A, et al. (1995) A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J. Clin. Invest. 95, 2397-2402.
14. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, et al. (1999) Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J. Clin. Invest. 104, 903-911.
15. Haymann J-P, Levraud J-P, Bouet S, Kappes V, Hagege J, Nguyen G, et al. (2000) Characterization and localization of the neonatal Fc receptor in adult human kidney. J. Am. Soc. Nephrol. 11, 632-639.
16. Israel EJ, Taylor S, Wu Z, Mizoguchi E, Blumberg RS, Bhan A, et al. (1997) Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 92, 69-74.
17. Simister NE, Story CM, Chen H-L, Hunt JS. (1996) An IgGtransporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur. J. Immunol. 26, 1527-1531.
18. Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, et al. (2002) Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life. J. Exp. Med. 196, 303-310.
19. Kim J-K, Tsen M-F, Ghetie V, Ward ES. (1994) Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur. J. Immunol. 24, 2429-2434.
20. Ashkenazi A, Capon D, Ward R. (1993) Immunoadhesins. Int. Rev. Immunol. 10, 219-227.
21. Chamow SM, Ashkenazi A. (1996) Immunoadhesins: principles and applications. Trends Biotechnol. 14, 52-60.
22. Martin MG, Wu SV, Walsh JH. (1997) Ontogenic development and distribution of antibody transport and Fc receptor mRNA expression in rat intestine. Dig. Dis. Sci. 42, 1062-1069.
23. Roberts DM, Guenthert M, Rodewald R. (1990) Isolation and characterization of the Fc receptor from the fetal yolk sac of the rat. J. Cell Biol. 111, 1867-1876.
24. Borvak J, Richardson J, Medesan C, Antohe F, Radu C, Simionescu M, et al. (1998) Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int. Immunol. 10, 1289-1298.
25. Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. (2009) Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. PNAS USA 106, 2788-2793.
26. Yoshida M, Masuda A, Kuo T, Kobayashi K, Claypool S, Takagawa T, et al. (2006) IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Semin. Immunopathol. 28, 397-403.
27. Telleman P, Junghans RP. (2000) The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology 100, 245-251.
28. Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. (2001) Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum. Immunol. 62, 93-105.
29. Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. (2004) Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J. Immunol. 172, 2021-2029.
30. Ward ES, Ober RJ, Frederick WA. (2009) Chapter 4. Multitasking by exploitation of intracellular transport functions: the many faces of FcRn. In: Advances in Immunology. Academic Press, pp. 77-115.
31. Bitonti AJ, Dumont JA. (2006) Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv. Drug Deliv. Rev. 58, 1106-1118.
32. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006) Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. Biodrugs 20, 151-160.
33. Low SC, Nunes SL, Bitonti AJ, Dumont JA. (2005) Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum. Reprod. 20, 1805-1813.
34. Graber SE, Krantz SB. (1978) Erythropoietin and the control of red cell production. Annu. Rev. Med. 29, 51-66.
35. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. (2005) Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol Med. 18, 294-303.
36. Farquhar MG. (1978) Recovery of surface membrane in anterior pituitary cells. Variations in traffic detected with anionic and cationic ferritin. J. Cell Biol. 77, 35-42.
37. Williams MC. (1984) Endocytosis in alveolar type II cells: effect of charge and size of tracers. Proc. Natl. Acad. Sci. USA 19, 6054-6058.
38. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. (2000) Multiple sclerosis. N. Engl. J. Med. 343, 938-952.
39. Rubinstein S, Familletti PC, Pestka S. (1981) Convenient assay for interferons. J. Virol. 37, 755-758.
40. Salmon P, Le Cotonnec J, Galazka A, Abdul-Ahad A, Darragh A. (1996) Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J. Interferon Cytokine Res. 16, 759-764.
41. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2009) Therapeutic Proteins from Bench to Clinic, Chapter 33. John Wiley & Sons, Inc., pp. 779-795.
42. Vallee S, Rakhe S, Reidy T,Walker S, Lu Q, Sakorafas P, et al. (2012) Pulmonary administration of IFN beta1a-Fc fusion protein in non-human primates using an immunoglobulin transport pathway. J. Interferon Cytokine Res. 32(4), 178-184.
43. Brassard DL, Grace MJ, Bordens RW. (2002) Interferon alpha as an immunotherapeutic protein. J. Leukoc. Biol. 71565- 581.
44. Kozlowski A, Milton Harris J. (2001) Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Release 72, 217-224.
45. Mannucci PM, Tuddenham EGD. (2001) The hemophilias: from royal genes to gene therapy. N. Engl. J. Med. 344, 1773-1779. REFERENCES 119
46. Soucie JM, Nuss R, Evatt B, et al. (2000) Mortality among males with hemophilia relationship with source of medical care: the hemophilia surveillance system project investigators. Blood, 96(2), 437-442.
47. Bjorkman S, Berntorp E. (2001) Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin. Pharmacokinet. 40, 815-832.
48. Bjorkman S., Folkesson A., Jonsson S. (2009) Pharmacoki ne tics a nd dos e requirements of f actor VIII ove r the age rang e 3-74 ye a rs: a popul ation analysis ba sed on 50 patients w i t h l o ng-t e r m p r o ph y l a c t i c t r e a t m e nt f o r h a e m o p h i l i a A. Eu r. J. C l i n. P h ar m a c ol. June 26, 2009. [Epub ahead of p r i nt ].
49. Sandberg H, Almstedt A, Brandt J, Gray E, Holmquist L, Oswaldsson U, et al. (2001) Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb. Haemost. 85, 93-100.
50. 1/495 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. USA 83, 5939-5942.
51. Graham JB, Buckwalter JA, Hartley LJ, Brinkhous KM. (1949) Canine hemophilia; observations on the course, the clotting anomaly, and the effect of blood transfusions. J. Exp. Med. 90, 97-111.
52. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC, et al. (2002) The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. PNAS USA 99, 12991-12996.
53. Dumont J, Liu T, Low S, Zhang X, Kamphaus GD, Sakorafas P, Fraley C, Drager D, Reidy T, McCue J, Franck HWG, Merricks EP, Nichols TC, Ashworth T, Franck H, Merricks EP, Nichols TC, Bitonti AJ, Pierce GF, Jiang H. (2012) Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 119(13), 3024-3030.
54. Powell J, Josephson NC, Quon, et al. (2011) Pharmacokinetics and safety of recombinant factor VIII Fc fusion protein (rFVIIIFc) in a Phase 1/2a trial in previously treated patients (PTPs) with severe hemophilia A. J. Thromb. Haemost. (s2), O-TU-073, 283.
55. Powell JS, Josephson NC, Quon D, Ragni MV, Cheng G, Li E, et al. (2012) Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood, 119(13), 3031-3037.
56. Bolton-Maggs PHB, Pasi KJ. (2003) Haemophilias A and B. Lancet 361, 1801-1809.
57. Green P, Naylor J, Giannelli F. (1995) The hemophilias. Adv. Genet. 32, 99-139.
58. Limentani SA, Roth DA, Furie BC, Furie B. (1993) Recombinant blood clotting proteins for hemophilia therapy. Semin. Thromb. Hemost. 19, 62-72.
59. Giangrande P. (2005) Haemophilia B: christmas disease. Expert Opin. Pharmacother. 6, 1517-1524.
60. Lin H-F, Maeda N, Smithies O, Straight DL, Stafford DW. (1997) A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90, 3962-3966.
61. Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, et al. (2010) Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 115, 2057-2064.
62. Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, et al. (1996) Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 88, 2603-2610.
63. McCarthy K, Stewart P, Sigman J, Read M, Keith JCJr, Brinkhous KM, et al. (2002) Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb. Haemost. 87, 824-830.
64. Shapiro AD, Ragni M, Valentino L, et al. (2010) Safety and prolonged biological activity following a single administration of a recombinant molecular fusion of native human coagulation factor IX and the Fc region of immunoglobulin G (IgG) (rFIXFc) to subjects with hemophilia B. Haemophilia 16(Suppl. 4), 30.
65. ShapiroAD, RagniMV, Valentino LA,Key NS, Josephson NC, Powell JS, et al. (2012) Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a Phase 1/2a study in hemophilia B patients. Blood 119(3), 666-672.
66. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. (2001) Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 98, 3600-3606.
67. BeneFIX1 (coagulation factor IX Recombinant) Summary of ProductCharacteristics forBeneFIX,ElectronicMedicinesCompendium10, http://www.medicines.org.uk/emc/medicine/37 6/ SP C /B e ne FIX /# PH AR MACO DY NA MI C P RO PS. accessed November 6, 2011.
68. Schaison G, Young J, Pholsena M, Nahoul K, Couzinet B. (1993) Failure of combined follicle-stimulating hormonetestosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 77, 1545-1549.
69. Schoot DC, Harlin J, Shoham Z, Mannaerts BMJL, Lahlou N, Bouchard P, et al. (1994) Endocrinology: recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin- deficient women. Hum. Reprod. 9, 1237-1242.
70. Steelman SL, Pohley FM. (1953) Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin. Endocrinology 53, 604-616.
71. Pierce JG, Parsons TF. (1981) Glycoprotein hormones: structure and function. Annu. Rev. Biochem. 50, 465-495.
72. Jia X-C, Hsueh AJW. (1986) Granulosa cell aromatase bioassay for follicle-stimulating hormone: validation and application of the method. Endocrinology 119, 1570-1577.
73. Keene JL, Matzuk MM, Otani T, Fauser BC, Galway AB, Hsueh AJ, et al. (1989) Expression of biologically active human follitropin in Chinese hamster ovary cells. J. Biol. Chem. 264, 4769-4775.
74. de Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L. (1996) Recombinat hormones: structure- function relationship of recombinant follicle stimulating hormone (Puregon1). Mol. Hum. Reprod. 2, 361-369.
75. Meachem SJ, McLachlan RI, de Kretser DM, Robertson DM, Wreford NG. (1996) Neonatal exposure of rats to recombinant follicle stimulating hormone increases adult Sertoli and spermatogenic cell numbers. Biol. Reprod. 54, 36-44.
76. Morris B, Morris R. (1974) The effects of cortisone acetate on stomach evacuation and the absorption of 125I-labelled globulins in young rats. J. Physiol. 240, 79-89.
77. Simister NE, Rees AR. (1985) Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur. J. Immunol. 15, 733-738.
78. Gillies S, Lan Y, Brunkhorst B, Wong W-K, Li Y, Lo K-M. (2002) Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol. Immunother. 51, 449-460.
79. Economides A, Carpenter L, Rudge J, Wong V, Koehler-Stec E, Hartnett C, et al. (2003) Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9, 47-52.
80. Cox GN, Smith DJ, Carlson SJ, Bendele AM, Chlipala EA, Doherty DH. (2004) Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp. Hematol. 32, 441-449.
81. Jazayeri JA, Carroll GJ. (2008) Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 22, 11-26.
82. Wang Q, Chen K, Liu R, Zhao F, Gupta S, Zhang N, et al. (2010) Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS ONE 5, e12734.
83. Goldzweig O, Hashkes PJ. (2011) Abatacept in the treatment of polyarticular JIA development clinical utility and place in therapy. Drug Des. Devel. Ther. 5, 61-70.
84. Gottlieb AB. (2005) Alefacept for psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 64, iv58-iv60.
85. Molineux G. (2011) The development of romiplostim for patients with immune thrombocytopenia. Ann. N.Y. Acad. Sci. 1222, 55-63.
86. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141-147.
87. Stahl N, Radin A, Mellis S. (2009) Rilonacept-CAPS and beyond. Ann. N.Y. Acad. Sci. 1182, 124-134.
88. Su VCh, Harrison J, Rogers C, Ensom MH. (2012) Belatacept: a new biologic and its role in kidney transplantation. Ann. Pharmacother. 46(1), 57-67.
89. Ohr M, Kaiser PK. (2012) Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin. Pharmacother. 13(4), 585-591.
90. Dwyer MA, Huang AJ, Pan CQ, Lazarus RA. (1999) Expression and characterization of a DNase I-Fc fusion enzyme. J. Biol. Chem. 274, 9738-9743.
91. Lee CH, Woo JH, Cho KK, Kang SH, Kang SK, Choi YJ. (2007) Expression and characterization of human growth hormone-Fc fusion proteins for transcytosis induction. Biotechnol. Appl. Biochem. 46, 211-217.
92. Hapuarachchi S, Fodor S, Apostol I, Huang G. (2011) Use of capillary electrophoresis-sodium dodecyl sulfate to monitor disulfide scrambled forms of an Fc fusion protein during purification process. Anal. Biochem. 414, 187-195.
93. Sahdev S, Khattar S, Saini K. (2008) Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies. Mol. Cell. Biochem. 307, 249-264.
94. De Pourcq K, De Schutter K, Callewaert N. (2010) Engineering of glycosylation in yeast and other fungi: current state and perspectives. Appl. Microbiol. Biotechnol. 87, 1617-1631.
95. Jacobs PP, Geysens S, VerveckenW, Contreras R, Callewaert N. (2008) Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology. Nat. Protoc. 4, 58-70.
96. Ghetie V, Ward ES. (2000) Multiple roles for the major histocompatibility complex class I related receptor FcRn. Annu. Rev. Immunol. 18, 739-766.
97. Roopenian DC, Akilesh S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725.
98. Ober RJ, Radu CG, Ghetie V,Ward ES. (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 13, 1551-1559.
99. McCue JT, Selvitelli K, Walker J. (2009) Application of a novel affinity adsorbent for the capture and purification of recombinant factor VIII compounds. J. Chromatogr. A 1216, 7824-7830.
100. Zhang J, Carter J, Siu S, O'Neill JW, Gates AH, Delaney J, et al. (2010) Fusion partners as a tool for the expression of difficult proteins in mammalian cells. Curr. Pharm. Biotechnol. 11, 241-245.